Table 3.

Recommendations for clinical dimensions of major depressive disorder

Dimension	First Intention	Second Intention
With marked anhedonia	SSRI or SNRI	α2-antagonist or agomelatine
With marked psychomotor retardation	SNRI. SSRI	Tricyclic or α2 antagonists
With marked sleep disturbances	SSRI or SNRI or α2-antagonist or agomelatine	Tricyclic ADT
With atypical features (hyperphagia, hypersomnia)	SSRI or SNRI	Tricyclic or agomelatine
With psychotic features	SNRI in monotherapy or SSRI in combination with an atypical antipsychotic	SSRI, tricyclic ADT or α2-antagonist, in monotherapy or in combination with AAP
With anxious features	SSRI or SNRI or α2 antagonist	Tricyclic ADT
With high suicidal risk	SSRI or SNRI or α2 antagonist	Tricyclic ADT or potentiation strategies with lithium or AAP

AAP Atypical Antipsychotic, SNRI Dual serotonin and norepinephrine reuptake inhibitors, SSRI Selective serotonin reuptake inhibitors